Similarly, Yu [61] found that in KRAS-mutant non-small cell lung cancer cells, cisplatin treatment increased overall m6A modification levels by regulating the post-translational modifications (PTMs) of ALKBH5, thereby enhancing DNA damage repair capacity and promoting resistance to platinum-based drugs. Here, KRAS is linked to non-small cell lung carcinoma.